<https://rdf.molmedb.upol.cz/reference/ref4222> <http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM494872>,
		<https://identifiers.org/molmedb/MM495329>;
	<http://purl.org/ontology/bibo/doi> "10.1021/acs.jmedchem.1c02175"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM494699>,
		<https://identifiers.org/molmedb/MM494871>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/bibliographicCitation> "Huckvale R, Harnden AC, Cheung KJ, Pierrat OA, Talbot R, Box GM, Henley AT, de Haven Brandon AK, Hallsworth AE, Bright MD, Akpinar HA, Miller DSJ, Tarantino D, Gowan S, Hayes A, Gunnell EA, Brennan A, Davis OA, Johnson LD, de Klerk S, McAndrew C, Le Bihan YV, Meniconi M, Burke R, Kirkin V, van Montfort RLM, Raynaud FI, Rossanese OW, Bellenie BR, Hoelder S.: Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 <i>In Vivo</i>. J Med Chem, Volume 65 (12), 2022"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/method30>,
		<https://rdf.molmedb.upol.cz/interaction/membrane18>;
	<http://purl.org/ontology/bibo/pmid> "35653645"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://rdf.molmedb.upol.cz/interaction/int1020582> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref4222> .
<https://rdf.molmedb.upol.cz/interaction/int1021640> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref4222> .
<https://rdf.molmedb.upol.cz/interaction/int1021078> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref4222> .
<https://rdf.molmedb.upol.cz/interaction/int1021079> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref4222> .
